Company Overview of Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. discovers and develops drugs in the field of epigenetics. The company discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders, and other diseases. Its pipeline includes bromodomain and extra-terminal proteins that regulate gene expression and small molecule inhibition; and EZH2, a histone lysine methyltransferase that works cooperatively as part of a multi-subunit complex known as PRC2. The company also provides target validation tools; biochemical, biophysical, and cell-based assays; and compound collections against targets in each of the writer, eraser, and reader classes. In addition, its discov...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Constellation Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2014.
Constellation Pharmaceuticals, Inc. Key Developments
Constellation Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Constellation Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Constellation Pharmaceuticals, Inc. Presents at BioFlorida Annual Conference, Oct-13-2014 02:00 PM
Oct 11 14
Constellation Pharmaceuticals, Inc. Presents at BioFlorida Annual Conference, Oct-13-2014 02:00 PM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Joe Collard, Co-Founder and CEO.
Constellation Pharmaceuticals, Inc. Announces New Preclinical Data on Novel Bet Bromodomain Inhibitors
Oct 8 13
Constellation Pharmaceuticals, Inc. announced the publication of a study in the Journal of Experimental Medicine demonstrating that small molecule inhibitors selectively targeting BET bromodomains can suppress T helper 17 (T 17) differentiation and T 17-mediated pathology in models of autoimmune diseases. The paper appears in the online early edition of J Exp Med published on October 7, 2013. During the last decade, researchers have uncovered the importance of T 17 cells as an integral part of the immune system that protects the human body from infections. However, this research has also shown that, when pathologically activated, these cells can attack multiple organs in the body and trigger autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Because of the important roles that T 17 cells play in both normal and dysregulated immune function, many academic, biotech and pharmaceutical laboratories have research programs devoted to targeting T 17 cells.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 5, 2014